Analysis Northwest Biotherapeutics, Inc. (0K95)
6/1/2024
Analysis of Northwest Biotherapeutics, Inc. (0K95)
Northwest Biotherapeutics, Inc. (symbol: 0K95) has been trading at a consistent price of 1.26100 for the past few days. The Relative Strength Index (RSI) indicator is at 0.00000, indicating a neutral position. The Moving Average Convergence Divergence (MACD) indicator is not available, suggesting a lack of trend direction.The Moving Average (MA) indicator matches the closing price, and the Simple Moving Average (SMA) is also at 1.26100. However, the Exponential Moving Average (EMA) and Weighted Moving Average (WMA) are not available for some of the recent days.
Overall, based on the limited data available, it seems that Northwest Biotherapeutics, Inc. is experiencing a period of stability with no clear trend direction indicated by the technical indicators. Further analysis with additional data points would be needed to provide a more comprehensive assessment of the stock's performance.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a positive current ratio, but a high total debt to equity ratio. The profit margin and operating margin are both healthy, indicating efficient operations. The company's fiscal year ends in September 2023, with notable figures such as revenue, EBITDA, and net income.
Moving on to stock statistics, key metrics such as short ratio, float shares, and shares outstanding are provided. The percentage held by insiders and institutions, as well as short interest, give insights into investor sentiment.
Valuation metrics show metrics like P/E ratio, PEG ratio, and price to book ratio, providing an indication of the company's valuation. The enterprise value, market capitalization, and other ratios offer further insights into the company's financial standing.
The stock price summary includes information on beta, moving averages, and the 52-week high and low prices, giving an overview of the stock's performance and volatility.
Lastly, dividends and splits data show dividend rates, payout ratios, and important dates related to dividends and stock splits, providing information for investors interested in the company's dividend policy.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a decrease in revenue from FY 2022 to FY 2023.
- Prior to the decrease, there was a consistent growth in revenue from FY 2020 to FY 2022.
- The revenue in FY 2023 is still higher than that in FY 2021 and FY 2020.
These trends indicate fluctuations in the company's revenue over the past four years, with a notable decrease in the most recent fiscal year.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been investing more in non-current assets over the years.
7. There is a fluctuating trend in current assets, possibly due to changes in short-term investments and receivables.
8. The company has been relying more on long-term debt to finance its operations.
9. Retained earnings have been a significant contributor to shareholders' equity.
10. The company needs to manage its current liabilities effectively to ensure liquidity.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational performance and strategic investments.
Earnings estimate
The analysts' estimates for future quarterly and annual earnings per share are as follows:1. Current Quarter (as of June 30, 2024):
- Average Estimate: $1.23
- Low Estimate: $1.18
- High Estimate: $1.26
- Year Ago EPS: $1.17
- Number of Analysts: 27
2. Next Quarter (as of September 30, 2024):
- Average Estimate: $1.42
- Low Estimate: $1.33
- High Estimate: $1.51
- Year Ago EPS: $1.35
- Number of Analysts: 26
3. Current Year (as of September 30, 2024):
- Average Estimate: $6.10
- Low Estimate: $5.95
- High Estimate: $6.41
- Year Ago EPS: $5.67
- Number of Analysts: 40
4. Next Year (as of September 30, 2025):
- Average Estimate: $6.69
- Low Estimate: $5.92
- High Estimate: $7.31
- Year Ago EPS: $6.10
- Number of Analysts: 40
Based on these estimates, we can see a generally positive trend in the expected earnings per share both quarterly and annually, with an increase projected for the upcoming periods compared to the previous year's performance. It indicates a growth trajectory in the company's profitability as forecasted by the analysts.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, the following conclusions can be drawn:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.6%
- The next quarter growth rate is 5.1%
- The current quarter growth rate is 5.1%
- The next year growth rate is 9.7%
- The average annual growth rate for the next 5 years is 9.7%
- The average annual growth rate for the past 5 years is 20.1%
It can be observed that the company is expected to experience a significant increase in growth compared to the past 5 years, with a particularly strong growth forecast for the next year and the next 5 years. The growth rates for the current and next quarter are more moderate in comparison.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it seems that the analysts are generally optimistic about the future price of the security, with a median and average price above the current price. However, there is a wide range between the low and high forecasts, indicating some uncertainty or differing opinions among analysts.
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
